INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-132871.3%−131197.1 pts over 5 years
Net margin
-130000.0%−127754.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -70.0% | -81.5% | -61.2% | -47.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -49.3% | -71.6% | -183.5% | |
| Return on assets | -38.1% | -48.7% | -90.6% | |
| Current ratio | 2.84 | 11.30 | 1.40 | |
| Interest coverage | – | -14.3× | – | |
| Capex to revenue | 7.7% | 20.5% | 437.2% | |
| Diluted shares | 6M | 13M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Inovio Pharmaceuticals generated $749.00M from operations and spent $3.29M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$749.00M
Used
$3.29M
Capital expenditure$3.29M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-130000.0%
×Asset turnover0.00×
×Equity multiplier2.02×
=Return on equity, FY2025-183.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -130000.0% | 0.00× | 2.02× | -183.5% |
| FY2024 | -49254.3% | 0.00× | 1.53× | -115.4% |
| FY2023 | -16239.9% | 0.00× | 1.53× | -79.5% |
| FY2022 | -2726.7% | 0.02× | 1.36× | -90.0% |
| FY2021 | -17109.9% | 0.00× | 1.20× | -70.6% |
| FY2020 | -2245.4% | 0.02× | 1.47× | -71.6% |
| FY2019 | -2902.8% | 0.03× | 3.04× | -264.2% |
| FY2018 | -318.1% | 0.19× | 1.39× | -84.6% |
| FY2017 | -208.9% | 0.23× | 1.36× | -66.4% |
| FY2016 | -208.5% | 0.18× | 1.30× | -49.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$84.95M
- Cash generatingOperating cash flow above zero-$88.63M
- Return on assets improvedROA up on the prior year-62.7% → -75.0%
- Earnings backed by cashOperating cash flow above net income-$88.63M vs -$84.95M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.77 → 1.40
- No dilutionShare count did not rise27M → 47M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00